Emerging Therapeutic Targets in Ovarian Cancer

Despite rapid advances in understanding the biology of ovarian cancer, progress in treatment has been slow. But the prospects for improvement have never been better. A wide range of novel therapeutic targets now present themselves for clinical evaluation and initial results are certainly encouraging...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Kaye, Stan (Επιμελητής έκδοσης), Brown, Robert (Επιμελητής έκδοσης), Gabra, Hani (Επιμελητής έκδοσης), Gore, Martin (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: New York, NY : Springer New York, 2011.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 02435nam a22004575i 4500
001 978-1-4419-7216-3
003 DE-He213
005 20151103151052.0
007 cr nn 008mamaa
008 101123s2011 xxu| s |||| 0|eng d
020 |a 9781441972163  |9 978-1-4419-7216-3 
024 7 |a 10.1007/978-1-4419-7216-3  |2 doi 
040 |d GrThAP 
050 4 |a RC261-271 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
082 0 4 |a 614.5999  |2 23 
245 1 0 |a Emerging Therapeutic Targets in Ovarian Cancer  |h [electronic resource] /  |c edited by Stan Kaye, Robert Brown, Hani Gabra, Martin Gore. 
264 1 |a New York, NY :  |b Springer New York,  |c 2011. 
300 |a XIII, 291 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
520 |a Despite rapid advances in understanding the biology of ovarian cancer, progress in treatment has been slow. But the prospects for improvement have never been better. A wide range of novel therapeutic targets now present themselves for clinical evaluation and initial results are certainly encouraging. In this text, all these areas are covered by experts in the field. Each chapter provides up-to-date coverage of clinical information, prefaced by a description of the rational basis for the selection of each target area and consideration of biomarkers that can be used to aid clinical evaluation. The four editors work together within the Ovarian Cancer Action collaborative research programme in London and they bring a wealth of laboratory and clinical expertise to this topic. The text should provide an invaluable source of reference for clinical and laboratory-based researchers working to meet the challenges of ovarian cancer. 
650 0 |a Medicine. 
650 0 |a Cancer research. 
650 0 |a Pharmacology. 
650 1 4 |a Biomedicine. 
650 2 4 |a Cancer Research. 
650 2 4 |a Pharmacology/Toxicology. 
700 1 |a Kaye, Stan.  |e editor. 
700 1 |a Brown, Robert.  |e editor. 
700 1 |a Gabra, Hani.  |e editor. 
700 1 |a Gore, Martin.  |e editor. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9781441972156 
856 4 0 |u http://dx.doi.org/10.1007/978-1-4419-7216-3  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642)